title: Uterine rupture during induced trial of labor among women with previous cesarean delivery.
abstract: OBJECTIVE
  This study was undertaken to compare the rates of uterine rupture during induced trials of labor after previous cesarean delivery with the rates during a spontaneous trial of labor.
  
  
  METHODS
  All deliveries between 1992 and 1998 among women with previous cesarean delivery were evaluated. Rates of uterine rupture were determined for spontaneous labor and different methods of induction.
  
  
  RESULTS
  Of 2119 trials of labor, 575 (27%) were induced. The overall rate of uterine rupture was 0.71% (15/2119). The uterine rupture rate with induced trial of labor (8/575; 1.4%) was significantly higher than with a spontaneous trial of labor (7/1544; 0.45%; P =.0004). Uterine rupture rates associated with different methods of induction were compared with the rate seen with spontaneous labor and were as follows: prostaglandin E(2) gel, 2.9% (5/172; P =.004); intracervical Foley catheter, 0.76% (1/129; P =.47); and labor induction not requiring cervical ripening, 0.74% (2/274; P =.63). The uterine rupture rate associated with inductions other than with prostaglandin E(2) was 0.74% (3/474; P =.38). The relative risk of uterine rupture with prostaglandin E(2) use versus spontaneous trial of labor was 6.41 (95% confidence interval, 2. 06-19.98).
  
  
  CONCLUSIONS
  Induction of labor was associated with an increased risk of uterine rupture among women with a previous cesarean delivery, and this association was highest when prostaglandin E(2) gel was used.
authors.affiliation: Department of Obstetrics and Gynecology, Foothills Hospital, University of Calgary, Alberta, Canada.
authors.forename: D J
authors.initials: DJ
authors.lastname: Ravasia
authors.forename: S L
authors.initials: SL
authors.lastname: Wood
authors.forename: J K
authors.initials: JK
authors.lastname: Pollard
mesh_terms: D002585:Cesarean Section; D036861:Delivery, Obstetric / Q000706:statistics & numerical data; D015232:Dinoprostone / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005782:Gels; D006801:Humans; D007751:Labor, Induced / Q000009:adverse effects*; D008499:Medical Records; D010120:Oxytocics / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D012307:Risk Factors; D014219:Trial of Labor; D014597:Uterine Rupture / Q000139:chemically induced / Q000209:etiology*
chemical_list: D005782:Gels; D010120:Oxytocics; D015232:Dinoprostone